Amity Island
Well-Known Member
- Relationship to Diabetes
- Type 1
- dapagliflozin 5 mg is no longer authorised for the treatment of patients with type 1 diabetes mellitus
- the removal of the type 1 diabetes indication is not due to any new safety concerns and the other indications of dapagliflozin are unchanged
- dapagliflozin should be reviewed and discontinued in patients with type 1 diabetes by or in consultation with a physician specialised in diabetes care as soon as clinically practical
- after stopping dapagliflozin treatment, frequent blood glucose monitoring is recommended
- an increased insulin dose may be needed, which should be undertaken carefully to minimise the risk of hypoglycaemia or hyperglycaemia
- diabetic ketoacidosis is a known risk with use of dapagliflozin in all patients with diabetes, but it occurs more frequently in patients with type 1 diabetes than those with type 2 diabetes
- additional risk minimisation materials to mitigate the risks in patients with type 1 diabetes are no longer available
- report suspected adverse drug reactions associated with use of dapagliflozin on a Yellow Card
Dapagliflozin (Forxiga): no longer authorised for treatment of type 1 diabetes mellitus
The authorisation holder for dapagliflozin has withdrawn the indication for type 1 diabetes mellitus. The removal of the type 1 diabetes indication is not due to any new safety concerns and the other indications of dapagliflozin are unchanged.
www.gov.uk